Pacira BioSciences, Inc. (PCRX) stock
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.02 (+0.05%)
Close on Nov 16, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Pacira BioSciences's operating income for the twelve months ending Jun 30, 2026 was $19.87M. For fiscal 2025 it was $19.19M. Over ten years it grew 7.3% a year on average. The highest annual figure on record is $89.92M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.19M | – |
| FY2024 | Dec 31, 2024 | -$73.37M | -183.7% |
| FY2023 | Dec 31, 2023 | $87.68M | +46.1% |
| FY2022 | Dec 31, 2022 | $60.02M | -33.3% |
| FY2021 | Dec 31, 2021 | $89.92M | +94.0% |
| FY2020 | Dec 31, 2020 | $46.35M | +342.3% |
| FY2019 | Dec 31, 2019 | $10.48M | -34.2% |
| FY2018 | Dec 31, 2018 | $15.92M | – |
| FY2017 | Dec 31, 2017 | -$24.94M | – |
| FY2016 | Dec 31, 2016 | -$32.02M | -438.7% |
| FY2015 | Dec 31, 2015 | $9.46M | – |
| FY2014 | Dec 31, 2014 | -$5.17M | – |
| FY2013 | Dec 31, 2013 | -$53.29M | – |
| FY2012 | Dec 31, 2012 | -$49.30M | – |
| FY2011 | Dec 31, 2011 | -$39.10M | – |
| FY2010 | Dec 31, 2010 | -$22.71M | – |
| FY2009 | Dec 31, 2009 | -$28.55M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.27M | -49.8% |
| Q1 FY2026 | Mar 31, 2026 | $6.90M | +246.8% |
| Q4 FY2025 | Dec 31, 2025 | $2.34M | -90.5% |
| Q3 FY2025 | Sep 30, 2025 | $6.36M | – |
| Q2 FY2025 | Jun 30, 2025 | $8.50M | -69.9% |
| Q1 FY2025 | Mar 31, 2025 | $1.99M | -84.9% |
| Q4 FY2024 | Dec 31, 2024 | $24.70M | -25.5% |
| Q3 FY2024 | Sep 30, 2024 | -$139.53M | -887.4% |
| Q2 FY2024 | Jun 30, 2024 | $28.24M | -29.2% |
| Q1 FY2024 | Mar 31, 2024 | $13.21M | – |
| Q4 FY2023 | Dec 31, 2023 | $33.17M | – |
| Q3 FY2023 | Sep 30, 2023 | $17.72M | -16.8% |
| Q2 FY2023 | Jun 30, 2023 | $39.88M | +27.7% |
| Q1 FY2023 | Mar 31, 2023 | -$3.09M | -117.8% |
| Q4 FY2022 | Dec 31, 2022 | -$9.89M | -334.9% |
| Q3 FY2022 | Sep 30, 2022 | $21.29M | -32.3% |
| Q2 FY2022 | Jun 30, 2022 | $31.24M | -10.4% |
| Q1 FY2022 | Mar 31, 2022 | $17.39M | -10.5% |
| Q4 FY2021 | Dec 31, 2021 | $4.21M | -77.6% |
| Q3 FY2021 | Sep 30, 2021 | $31.43M | +78.4% |
| Q2 FY2021 | Jun 30, 2021 | $34.84M | – |
| Q1 FY2021 | Mar 31, 2021 | $19.44M | +13.7% |
| Q4 FY2020 | Dec 31, 2020 | $18.78M | +995.8% |
| Q3 FY2020 | Sep 30, 2020 | $17.62M | +630.2% |
| Q2 FY2020 | Jun 30, 2020 | -$7.15M | -235.5% |
| Q1 FY2020 | Mar 31, 2020 | $17.09M | +1484.2% |
| Q4 FY2019 | Dec 31, 2019 | $1.71M | -86.0% |
| Q3 FY2019 | Sep 30, 2019 | $2.41M | -40.4% |
| Q2 FY2019 | Jun 30, 2019 | $5.28M | -19.4% |
| Q1 FY2019 | Mar 31, 2019 | $1.08M | – |
| Q4 FY2018 | Dec 31, 2018 | $12.26M | +44.9% |
| Q3 FY2018 | Sep 30, 2018 | $4.05M | – |
| Q2 FY2018 | Jun 30, 2018 | $6.54M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.94M | – |
| Q4 FY2017 | Dec 31, 2017 | $8.46M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.57M | – |
| Q2 FY2017 | Jun 30, 2017 | -$15.78M | – |
| Q1 FY2017 | Mar 31, 2017 | -$14.05M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.46M | – |
| Q3 FY2016 | Sep 30, 2016 | -$20.87M | – |
See a number that looks wrong?